Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
42 results about "Human endometrium" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Combination progestin oral contraceptive regimen
InactiveUS20010020015A1Reducing breakthrough bleedingBiocideOrganic active ingredientsRegimenPhysiology
An oral contraception regimen which comprises sequentially administering two or more progestational agents exhibiting different effects on the human endometrium in combination with an estrogen. The invention is also directed to an extended use oral contraception regimen comprising the sequential administration of two or more progestational agents in combination with an estrogen.
Owner:ORTHO MCNEIL PHARM INC
Method for detecting endometrial receptivity through MST1 and phosphorylated MST1
ActiveCN105988002AQuick and easy expressionEasy and fast retouching levelMaterial analysisCarcinoma cell linePhosphorylation
The invention provides a method for detecting endometrial receptivity through MST1 and phosphorylated MST1. The method comprises the steps that a human endometrial carcinoma cell line Ishikawa and HEK293T cells are kept and cultured in a 10% FBS and mycillin containing double-antibody DMEM / F12 culture solution; an immunoblotting experiment is carried out; co-immunoprecipitation is carried out; immunohistochemistry is carried out; adjustment of MST1 on the transcriptional activity of HOXA10 is analyzed through chromosome co-immunoprecipitation (ChIP) / PCRs; human choriocarcinoma cell (BeWo) sphere adhering experiments are carried out. According to the method, the expression level of MST1 and MST1 phosphorylation modification in endometrial tissue is detected conveniently and fast, and the receptivity state of the endometrium can be directly reflected.
Owner:江苏华朵生物科技有限公司
Human tumor-related methylation site as well as screening method and use thereof
ActiveCN107190076AEarly diagnosisMicrobiological testing/measurementDNA/RNA fragmentationHuman tumorScreening method
The invention provides a human tumor-related methylation site as well as a screening method and use thereof. The human tumor-related methylation site is selected from at least one methylation site on a human 18th chromosome, a human third chromosome and a human second chromosome; the change of methylation site, caused by BMI, on chromosomes is related to a human endometrial cancer; prognosis on a human tumor can be performed by detecting the methylation site changes on the chromosomes; the human tumor-related methylation site can be used as a potential prognosis marker of the tumor, and especially can be used as a prognosis marker of the human endometrial cancer.
Owner:SUZHOU INST OF BIOMEDICAL ENG & TECH CHINESE ACADEMY OF SCI +1
Preparation containing autologous endometrium mesenchymal cell exosome
PendingCN108815189APreserve and use activitySave and utilize functionsPharmaceutical delivery mechanismSkeletal/connective tissue cellsDiseaseMatrix solution
The invention provides a preparation containing endometrium mesenchymal cell exosome, and relates to the technical field of biological stem cells. The preparation comprises, by volume, 5 parts of endometrium mesenchymal cell exosome and 95 parts of matrix solution. The matrix solution comprises 95-99 parts of multiple electrolytes injection liquid and 1-5 parts of medicinal human blood albumin, and endometrium mesenchymal cell exosome is derived from starvation culture of autologous endometrium mesenchymal cells, and the time of the starvation culture is 12-24 hours. The autologous endometriummesenchymal cells are extracted from the mesenchymal stem cells in a human endometrium and cultured by using a normal culture method. The culture time is 48-72 hours. The invention provides a medicine which is safe, effective and convenient to use for treating diseases such as endometrial damage and the like.
Owner:天津欣普赛尔生物医药科技有限公司
Method for culturing and proliferating hematopoietic stem cells and progenitor cells using human endometrial cells
Disclosed herein is a method for culturing and proliferating hematopoietic stem cells or progenitor cells. The method comprises co-culturing the hematopoietic stem cells or the progenitor cells with human endometrial stromal cells so as to promote the expansion of hematopoietic stem cell-derived CD34+ cells or the growth of the progenitor cells. According to the disclosed method, unlike the prior methods of culturing the hematopoietic stem cells with the addition of cytokines, growth factors or hormones, the hematopoietic stem cells or the progenitor cells are co-cultured with the endometrial stromal cells or epithelial cells so that the number of CD34+-enriched hematopoietic stem cells or progenitor cells is increased by factors secreted from the endometrial stromal cells or epithelial cells. Accordingly, it is possible to eliminate the addition of growth factors, such as cytokines, and hormones, which cause problems in transplantation of hematopoietic stem cells or progenitor cells and thus safe hematopoietic stem cells or progenitor cells can be obtained in large amounts.
Owner:SEOUL NAT UNIV R&DB FOUND
Marker molecules at different time points in endometrial secretion period and screening method thereof
PendingCN113295815AFacilitate further understanding of physiological changesIncrease success rateComponent separationEmbryo transplantationPhosphorylation
The invention discloses a protein extraction and treatment process at different time points (including early, middle and late periods of secretion: LH_2, LH_5, LH_7, LH_9, LH_10 and LH_12, and LH_0 on the day of injection of hCG) in a human endometrial tissue secretion period, and a protein spectrum and a phosphorylation modification mass spectrum are carried out to obtain molecular expression modes at different time points in the secretion period. The molecular expression modes can provide a basis for further knowing the dynamic change of the human endometrial tissue secretion period, and is beneficial to judging an endometrial implantation window period and guiding the embryo transplantation time in an assisted reproduction technology.
Owner:NANJING DRUM TOWER HOSPITAL
Endometrial stem cell exocrine concentrated solution gel preparation for treating endometrial injury, preparation method and drug administration method of preparation
InactiveCN109908180AImprove stabilityHigh activityAerosol deliveryOintment deliveryGel preparationHigh concentration
The invention discloses an endometrial stem cell exocrine concentrated solution gel preparation for treating endometrial injury, a preparation method and a drug administration method of the preparation. A method of starving endometrial stem cells is adopted to obtain a human endometrial stem cell exocrine extract in a short time, and the extract is concentrated through an ultracentrifugation method to obtain a human endometrial stem cell exosome with high concentration, wherein the gel for the human endometrial stem cell exosome contains sodium alginate and a compound electrolyte injection solution as stabilizers, a humectant and a transdermal absorption promoter to form stable and uniform gel-like substances which are beneficial to absorption. The preparation can be used for treating endometrial injury.
Owner:天津欣普赛尔生物医药科技有限公司
Application of Gamabufotalin and salt thereof in preparing medicament for treating gynaecologic tumor
InactiveCN101485666AActive ingredient clearQuality is easy to controlOrganic active ingredientsSteroidsGynecologic TumorEndometrial cancer
The invention provides application of gamabufotalin and a salt compound thereof in preparation of a medicine for treating gynecological tumor. By comparing in vitro anti-cancer experiments of a bufadienolide extract and monomeric compounds, namely the gamabufotalin, cinobufagin, bufalin and bufotalin as well as hydrochlorides or sulfates of the four compounds to four gynecological tumors, namely human ovarian cancer cells A2780, human ovarian cancer cells SK-OV-3, human cervical carcinoma cells and human endometrial cancer cells, an experimental result shows that the gamabufotalin has stronger activity against gynecological tumor cells than the bufadienolide extract and the monomeric compounds, namely the cinobufagin, the bufalin and the bufotalin, and the hydrochloride or the sulfate of the gamabufotalin has stronger activity against gynecological tumor cells than the hydrochlorides or the sulfates of three compounds, namely the cinobufagin, the bufalin and the bufotalin. The gamabufotalin and the salt compound thereof provided by the invention have the advantages of clear components, controllable quality, strong anti-cancer activity, and small adverse reaction, and are expect to be developed into a novel anti-cancer drug.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Marker of human endometrial cancer, antibody and application of antibody
InactiveCN105859872AImmunoglobulins against cell receptors/antigens/surface-determinantsTissue cultureEpitopeCD44
The invention discloses a new human endometrial cancer tumor marker through immune mice from human endometrial cancer oncoprotein. The marker is named GAB31, and is abnormally glycosylated CD44. The marker is characterized in that CD44 contains a saccharide structure Galb1-3(Neu5Aca2-6)GlcNAcb1-4Galb1-4Glcb of epitope; in addition, a monoclonal antibody of the antigen is specifically recognized through screening, an antibody capable of specifically recognizing the antigen is obtained, and it is found through immunomagnetic bead experiments for clinical samples that the EM2D9-MB positive detection rate of a detecting method that the antibody recognizes the antigen GAB31 is obviously higher than that of a conventional cast-off cell microscopic examination method.
Owner:王闳
Applications of human endometrium stem cells in preparation of drugs for premature ovarian failure treatment
The present invention relates to a new method for premature ovarian failure treatment, wherein human endometrium stem cells can promote ovarian function recovery. Particularly the present invention discloses applications of human endometrium stem cells in preparation of drugs for premature ovarian failure treatment, specifically in preparation of cell drugs for premature ovarian failure treatment, and / or medical technologies.
Owner:THE INT PEACE MATERNITY & CHILD HEALTH HOSPITAL OF CHINA WELFARE INST +1
Composition for improving premature ovarian failure, preparation method therefor and application of composition
PendingCN113244272AImprove premature agingReduce inflammationCulture processUnknown materialsDiseasePhysiology
The invention belongs to the technical field of biomedicines and particularly relates to a composition for improving premature ovarian failure, a preparation method therefor and application of the composition. According to the composition for improving the premature ovarian failure, provided by the invention, an in-vitro-constructed human uterine endometrium stem-cell cell membrane and a mesenchymal stem cell exosome are used in a compounded manner, thus, the development of ovarian follicles can be promoted, ovaries can be promoted to secrete an anti-Mullerian hormone, an ovarian follicle generator promoting level can be regulated, the apoptosis of ovarian cells can be inhibited, the adverse reserve function disease of the ovaries can be improved, the effect of improving primary or secondary premature ovarian failure is good, and thus, a new way of think is provided for clinically treating ovarian insufficiency and polycystic ovarian syndrome.
Owner:陕西中鸿科瑞再生医学研究院有限公司
Use of bufadienolides compound and bufadienolides salinization compound in preparing medicine for treating gynecological tumor
InactiveCN101491531AClear ingredientsLow effective doseOrganic active ingredientsSteroidsGynecologic TumorEndometrial cancer
The invention provides application of a bufadienolide compound and a bufadienolide salt compound in preparing a medicine for treating gynecological tumor. Anti-cancer experiments of four gynecological tumor, namely human ovarian cancer cells (A2780), human ovarian cancer cells (SK-OV-3), human cervical carcinoma cells (SiHa) and human endometrial cancer cells (shikawa) are carried out in vitro through a bufadienolide extract and monomeric compounds, namely cinobufagin, bufalin, bufotalin and gamabufotalin as well as hydrochlorides or sulfates of the four monomeric compounds, and an experimental result shows that the bufadienolide extract, the monomeric compounds, namely the cinobufagin, the bufalin, the bufotalin and the gamabufotalin, and the hydrochlorides or the sulfates of the four monomeric compounds have strong inhibition effect on four gynecological tumor cells. The anti-cancer activity of the bufadienolide compound and the bufadienolide salt compound is stronger than that of a positive drug paclitaxel, and the bufadienolide compound and a bufadienolide salt compound have small adverse reaction and expect to be developed into a novel anti-cancer drug.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Stem cell exosome composite preparation for improving premature ovarian failure and application of composite preparation
InactiveCN110638834APrevention and treatment of premature agingImprove actual functionsUnknown materialsSkeletal/connective tissue cellsMesenchymal stem cellExosome
The invention belongs to the technical field of biology, and particularly relates to a stem cell exosome composite preparation for improving premature ovarian failure and an application of the composite preparation. The stem cell exosome composite preparation provided by the invention is formed by compounding human endometrial stem cell exosomes and human umbilical cord mesenchymal stem cells, human endometrial stem cells are selected as a source of the stem cell exosomes, the exosomes are collected after culture, and the exosomes and a certain amount of the highly-active human umbilical cordmesenchymal stem cells are mixed for use to maximize the function of the exosomes and the stem cells, so that the ovarian physiological function can be effectively improved, and ovarian decline can bedelayed. The invention also provides the application of the above stem cell exosome composite preparation in treating the premature ovarian failure and improving hormone secretion.
Owner:陕西中鸿科瑞再生医学研究院有限公司
Method for establishing human endometritis model in vitro by using berberine to alleviate lipopolysaccharide
PendingCN110055211ACell dissociation methodsArtificial cell constructsScreening methodConcentration gradient
The invention relates to a method for establishing a human endometritis model in vitro by using berberine to alleviate lipopolysaccharide. The method comprises the steps of (1) isolation and culture of primary human endometrial stromal cells: using primary cell culture in vitro and the secondary screening method to extract 2-3 generations of human endometrial stromal cells; (2) utilizing the CCK8method to screen the appropriate concentration and time of LPS on the cells; (3) adopting the CCK8 method to screen the appropriate concentration and time of BBR on the cells; (4) detecting the content of IL-1 beta and TNF-alpha by ELISA; (5) data analysis. The CCK8 method is adopted to detect the toxic effects of different concentration gradients of LPS and BBR on hESCs at the different time, andthe ELISA method is utilized to identify an LPS-induced inflammation model to determine that berberine has a certain curative effect on human endometritis and is a potential drug for treating the endometritis.
Owner:THE FIRST HOSPITAL OF LANZHOU UNIV
Preparation for treating premature ovarian failure and preparation method
InactiveCN108815190ARepair structureRestoration of endocrine functionUnknown materialsSexual disorderEndocrine functionsMatrix solution
The invention provides a preparation for treating premature ovarian failure and a preparation method, and relates to the technical field of biological stem cells. The preparation is prepared from autologous endometrial mesenchymal stem cells and a matrix solution, the matrix solution is prepared from compound electrolytes injection, oestrogen and medicinal human blood albumin, the autologous endometrial mesenchymal stem cells are extracted from human endometrial mesenchymal stem cells, the preparation is obtained through culture according to a normal culture method, the preparation survival time is longer, the preparation can be used for repairing an ovary structure, the endocrine function of the ovary is recovered, and the premature ovarian failure is effectively treated.
Owner:天津欣普赛尔生物医药科技有限公司
Application of glycocholic acid in preparation of antitumor drugs
InactiveCN109575100AImprove developmentOrganic active ingredientsSteroidsBULK ACTIVE INGREDIENTWilms' tumor
The invention relates to application of chemical drugs in the field of medicine, in particular to application of glycocholic acid in preparation of antitumor drugs. The novel applicable field of glycocholic acid is provided herein; glycocholic acid is applicable to the preparation of antitumor drugs, mainly for breast cancer, ovarian cancer, endometrial carcinoma, lung cancer or their combinations; as an effective active ingredient to antitumor drugs, glycocholic acid has effective treatment quantity of 4T1 (mouse breast cancer cells) under 0.4-1.6 nmol / L, and MCF-7 (human breast cancer cells), NIH OVCAR-3 (human ovarian carcinoma cells), RL95-2 (human endometrial cancer cells), and HCC827 (human non-small cell lung cancer cells) under 16-128 mu mol / L. The application is helpful for the development of novel antitumor drugs.
Owner:DALIAN UNIV
Isolated culture method for human endometrial tissue-derived endothelial progenitor cell
ActiveCN109055300ACell dissociation methodsEpidermal cells/skin cellsSurface markerSingle cell suspension
The invention relates to an isolated culture method for a human endometrial tissue-derived endothelial progenitor cell. The endometrial tissue-derived endothelial progenitor cell is isolated from thehuman endometrial tissue. After an enzymolysis method is used for digesting the human endometrial tissue to obtain single-cell suspension, a density gradient centrifugation method is adopted to isolate to obtain a cell group which contains endothelial progenitor, the cell group is inoculated in an endothelial progenitor cell culture medium to carry out culture and passage purification, and finally, a new endothelial progenitor cell with an ultrastrong angiogenesis ability is obtained. An experiment proves that the endothelial progenitor cell has self proliferation and clone sample growth abilities, has an endothelial progenitor cell surface marker, also has the abilities of uptaking Dil-ac-LDL, combining with FITC-UEA-1 and forming tubular structures in vitro, and can be used for preparingmedicines capable of preventing or treating ischemic diseases.
Owner:SHANXI MEDICAL UNIV
Method for building external nidation model of embryo body and usage
InactiveCN1873738AInhibit growthPromote reproductionEmbryonic cellsEducational modelsLife qualityBiology
The invention discloses a method for establishing an embryo in vitro implantation model and the user thereof, and the method comprises the courses of: endometrium selection, separate culture and deciduate induction of substrate cells of human endometrium and, embryo culture, co-culture of human embryo and substrate cells of deciduate endometrium, etc, and because it establishes a model of in vitro co-culturing substrate cells of deciduate human endometrium and human embryo and has observed the whole implantation course of human embryo, including adhesion, epitaxial growth and invasion. And the model is nearer to human embryo in vitro implantation environment, and can be used to make a series of researches on related influence factors of embryo implantation, implements in vitro observation of human embryo implantation and provides conditions for researching human embryo implantation mechanism. And the invention can improve sterility curing level and auxiliary procreation technical level, and has great social and economical benefits.
Owner:刘芳
Uses of loganetin in preparation of antitumor medicines
ActiveCN107362158AWide range of anti-tumorEnhanced inhibitory effectOrganic active ingredientsRespiratory disorderMalignant lymphomaHuman leukemia
The invention belongs to the technical field of medicines, and relates to uses of loganetin in preparation of antitumor medicines. Tumors here include mammal gastric cancer, liver cancer, esophagus cancer, colorectal cancer, pancreatic cancer, lung cancer, head and neck cancer, leukemia, malignant lymphoma, prostatic cancer, breast cancer, glioma, carcinoma of bile duct, melanoma, kidney cancer, ovarian cancer, endometrial cancer and cervical cancer, and more specifically, human gastric cancer, human liver cancer, human esophagus cancer, human colorectal cancer, human pancreatic cancer, human lung cancer, human head and neck cancer, human leukemia, human malignant lymphoma, human prostatic cancer, human breast cancer, human glioma, human carcinoma of bile duct, human melanoma, human kidney cancer, human ovarian cancer, human endometrial cancer and human cervical cancer. In-vitro and in-vivo tests prove that the loganetin can inhibit the tumors well, shows good tumor growth inhibiting activity, and has great potential in development into antitumor medicines.
Owner:SHANDONG NEWTIME PHARMA
Human endometriosis cell
The present invention discloses a human endometriosis cell, EM 257, which has been stored in the food industry research and development institute. Results obtained from a flow cytometry reveal that the human endometriosis cell of the present invention is positive for the mesnchymal stem cell surface antigens, such as CD44, CD73, CD105 and CD146. In different differentiation conditions, the human endometriosis cell of the present invention can be differentiated into osteogenic or adipogenic lineage cells.
Owner:NATIONAL CHANGHUA UNIVERSITY OF EDUCATION
A method for evaluating endometrial receptivity of patient and kit for performing method
The invention provides a method for evaluating endometrial receptivity of a patient and a kit for performing the method. According to the invention, the human endometrial receptivity functional statusis determined by using RNA or DNA sequencing (e.g., by NGS (next generation sequencing)) of a living tissue examination material from the endometrium, and using the expression of 248 genes related tothe endometrial receptivity status or a specific sub-combination thereof (as shown in Figure 1). Based on analysis, specific computational predictors classify samples according to their expression profiles in corresponding endometrial stages (proliferation stage, pre-receptive stage, early receptive stage, receptive stage, late receptive stage or post-receptive stage). It should be noted that thereceptivity statuses can be assigned through subsequent analysis of expression profiles of a specific gene set by the computational predictors.
Owner:IGENOMIX SL
Molecular marker CD71 and applications in diagnosis, staging and prognosis of endometrial carcinoma
InactiveCN107102141ANot limited to immunohistochemical detectionBiological material analysisBiologyTransferrin receptor
The present invention relates to a molecular marker CD71 and applications in diagnosis, staging and prognosis of endometrial carcinoma, and belongs to the field of molecular biology, wherein the molecular marker is human transferrin receptor 1 (CD71). According to the present invention, by using the anti-human transferrin receptor 1 (CD71) antibody, the results show that human transferrin receptor 1 (CD71) is not expressed or extremely little expressed in normal endometrial tissue and precancerous lesion tissue, is specifically and highly expressed in human endometrial carcinoma tissue, and is related to the staging and the prognosis of endometrial carcinoma, such that CD71 can be used in the diagnosis, the clinical staging and the prognosis of endometrial carcinoma tissue.
Owner:INSITUTE OF BIOPHYSICS CHINESE ACADEMY OF SCIENCES
Human endometrial adenocarcinoma cell line and establishing method thereof
ActiveCN106479981AStable in vitro proliferationStable transfer abilityMicroorganism based processesTumor/cancer cellsMammalBasic research
The invention discloses a human endometrial adenocarcinoma cell line and an establishing method thereof. The human endometrial adenocarcinoma cell line is collected in the China General Microbiological Culture Collection Center (CGMCC) with the collection number CGMCC No. 12290. The establishing method comprises the following steps: (A) acquiring a fresh clinical endometrial adenocarcinoma surgical resection specimen, and performing cell separation primary culture with an II collagenase digestion method; (B) when the cell confluence degree is about 90 percent, performing cell passage culture to finish line establishment of hEMC20121018. The human endometrial adenocarcinoma cell line has a stable cell biological characteristic, an HER-2 gene encoding protein is expressed highly, and a tumor can be formed in a mammal. The human endometrial adenocarcinoma cell line can be directly applied to relevant important researches of cell biology, molecular biology and antitumor drug screening, and is an ideal human endometrial adenocarcinoma cell line applied to fundamental researches and pre-clinical applications.
Owner:THE FIRST HOSPITAL OF CHINA MEDICIAL UNIV +1
Method For Creating Endometriotic Cells And Endometriosis Model Animal
InactiveUS20160192626A1Improve the level ofCulture processArtificial cell constructsCell-Extracellular MatrixECM Protein
Provided is a method of producing a cell having properties of endometriosis (hereinafter referred to as “endometriotic-like cell”) from a human mesenchymal stem cell. Also provided are a method of producing an animal model exhibiting human endometriosis, the method including transplanting the cell to an animal, and an animal model of endometriosis. The method of producing an endometriotic-like cell comprises a step of culturing a human mesenchymal stem cell induced to differentiate by allowing a differentiation inducing agent to act on the cell, through use of a low-carbon-source culture medium free of a differentiation inducing agent, in a culture vessel coated with extracellular matrix.
Owner:KYOTO UNIV +1
Preparation method and application of human endometrial stem cell compound repair factor
PendingCN110384716AEfficient removalGood treatment effectCell dissociation methodsAntipyreticSide effectIn vitro digestion
The invention discloses a preparation method and application of a human endometrial stem cell compound repair factor. The preparation method specifically includes the following steps that a human endometrial stem cell is separated from human endometrial tissue; in-vitro digestion separation and expanded culture is performed on the human endometrial stem cell to obtain a high-quality human endometrial stem cell; industrialized amplification culture is performed on the high-quality human endometrial stem cell, and stem cell culture supernatants of the P3-P6 generations are collected; the stem cell culture supernatants are subjected to concentration, protein content determination and quality inspection to obtain a human endometrial stem cell concentration factor; the human endometrial stem cell concentration factor is mixed with a freeze-drying protective agent, and then freeze-drying is conducted to obtain human endometrial stem cell freeze-dried powder; and the human endometrial stem cell freeze-dried powder is mixed with a solvent to obtain the human endometrial stem cell compound repair factor. The repair factor has a remarkable treatment effect, a patient is free of pain, an operation and a surgery are not required, no side effect is caused, and the factor is safe and efficient.
Owner:杨永利
Gene expression profile as an endometrial receptivity marker
The present invention relates to determining the receptivity of human endometrium from a gene expression profile. More specifically, the invention consists of developing a specific expression microarray of endometrial receptivity (Endometrial Receptivity Array or ERA) which allows evaluating the receptive state of a human endometrium, as well as assessing said state for diagnostic and therapeutic purposes.
Owner:IGENOMIX SL
A kind of human endometrial cancer cell line and its establishment method
ActiveCN106479981BStable in vitro proliferationStable transfer abilityMicroorganism based processesTumor/cancer cellsCell separationDigestion
Owner:THE FIRST HOSPITAL OF CHINA MEDICIAL UNIV +1
A strain of endometrial adenocarcinoma cell lines
The invention discloses a strain of endometrial adenocarcinoma cell lines, wherein a name of the endometrial adenocarcinoma cell lines is LHY-821, and a preservation register number of the endometrial adenocarcinoma cell lines is CGMCC No.4066. The LHY-821 cell lines has advantages of uniform cell morphology, good cell growth, strong adhesive ability, doubling time of 44-48 hours and stable biological characteristics and genetic property. The LHY-821 cell lines can be applicable for research on biology of tumor cells, molecular biology, gene and epigenetics in vitro and in vivo, and on therapeutic effects of new antitumor drugs in a preclinical phase, and has a wide application prospect.
Owner:廖秦平 +5
Application of Gamabufotalin and salt thereof in preparing medicament for treating gynaecologic tumor
InactiveCN101485666BActive ingredient clearQuality is easy to controlOrganic active ingredientsSteroidsCancer cellGynecologic Tumor
The invention provides application of gamabufotalin and a salt compound thereof in preparation of a medicine for treating gynecological tumor. By comparing in vitro anti-cancer experiments of a bufadienolide extract and monomeric compounds, namely the gamabufotalin, cinobufagin, bufalin and bufotalin as well as hydrochlorides or sulfates of the four compounds to four gynecological tumors, namely human ovarian cancer cells A2780, human ovarian cancer cells SK-OV-3, human cervical carcinoma cells and human endometrial cancer cells, an experimental result shows that the gamabufotalin has stronger activity against gynecological tumor cells than the bufadienolide extract and the monomeric compounds, namely the cinobufagin, the bufalin and the bufotalin, and the hydrochloride or the sulfate of the gamabufotalin has stronger activity against gynecological tumor cells than the hydrochlorides or the sulfates of three compounds, namely the cinobufagin, the bufalin and the bufotalin. The gamabufotalin and the salt compound thereof provided by the invention have the advantages of clear components, controllable quality, strong anti-cancer activity, and small adverse reaction, and are expect tobe developed into a novel anti-cancer drug.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Use of bufadienolides compound and bufadienolides salinization compound in preparing medicine for treating gynecological tumor
InactiveCN101491531BClear ingredientsLow effective doseOrganic active ingredientsSteroidsGynecologic TumorEndometrial cancer
The invention provides application of a bufadienolide compound and a bufadienolide salt compound in preparing a medicine for treating gynecological tumor. Anti-cancer experiments of four gynecological tumor, namely human ovarian cancer cells (A2780), human ovarian cancer cells (SK-OV-3), human cervical carcinoma cells (SiHa) and human endometrial cancer cells (shikawa) are carried out in vitro through a bufadienolide extract and monomeric compounds, namely cinobufagin, bufalin, bufotalin and gamabufotalin as well as hydrochlorides or sulfates of the four monomeric compounds, and an experimental result shows that the bufadienolide extract, the monomeric compounds, namely the cinobufagin, the bufalin, the bufotalin and the gamabufotalin, and the hydrochlorides or the sulfates of the four monomeric compounds have strong inhibition effect on four gynecological tumor cells. The anti-cancer activity of the bufadienolide compound and the bufadienolide salt compound is stronger than that of apositive drug paclitaxel, and the bufadienolide compound and a bufadienolide salt compound have small adverse reaction and expect to be developed into a novel anti-cancer drug.
Owner:NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com